
Zhitong Finance App News, WuWu Biology (300357.SZ) issued an announcement. Recently, the “Dermatitis Diagnostic Patch 01 Patch” and “Dermatitis Diagnostic Patch 02 Patch” (“Dermatitis Diagnostic Patch R&D Project”) developed by the company completed phase II and phase I clinical studies respectively, and obtained clinical trial summary reports. In order to rationally allocate the company's R&D resources and focus on superior projects in the R&D pipeline, due to factors such as low synergy with the company's other dermatitis diagnostic patches in the research pipeline, limited clinical testing requirements for some adaptogens, and the risk of subsequent clinical promotion of the project, it was decided to stop the dermatitis diagnostic patch research and development project after careful evaluation by the company's management.
As of the disclosure date of the announcement, the total balance of development expenses for the dermatitis diagnostic patch research and development project was 7.9197 million yuan. According to the “Corporate Accounting Standards” and the company's relevant financial accounting system, the company fully prepared for impairment of 7.9197 million yuan after performing impairment tests on the aforementioned project development expenses. The above matters will reduce the company's total profit in 2026 by 7.9197 million yuan; after considering the impact of corporate income tax, the company's net profit attributable to shareholders of listed companies in 2026 will be reduced by 5.5455 million yuan.